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Background/aim: We aimed to evaluate the utility of thyroid imaging reporting and data system (TI-RADS) in prediction of malignancy
in thyroid nodules with persistent nondiagnostic (ND) cytology.
Materials and methods: A total of 246 thyroid nodules which were surgically removed and had at least two fine-needle aspirations
(FNAs) with ND cytology were included in this study. Ultrasonography features and TI-RADS scores were recorded.
Results: Of 246 nodules, 218 (88.6%) had benign and 28 (11.4%) had malignant final histopathology. Frequencies of taller than wide
shape, solidity, hypoechogenicity, microcalciﬁcations, and presence of irregular borders were similar between benign and malignant
nodules (P > 0.05). The number of nodules categorized as TI-RADS 3, 4a, 4b, and 4c were 12 (4.9%), 53 (21.5%), 104 (42.3%), and 77
(31.3%), respectively. There was not any nodule in TI-RADS 5 category. Malignancy rates of categories 3, 4a, 4b, and 4c were 0%, 13.2%,
9.6%, 14.3%, respectively. No significant differences were detected in TI-RADS categories between benign and malignant nodules (P
> 0.05).
Conclusion: In this study, we did not demonstrate any suspicious ultrasound (US) finding predictive for malignancy in thyroid nodules
with persistent ND cytology and did not determine any difference between malignant and benign nodules regarding TI-RADS scores.
Whereas, we found that thyroid nodules in 4a, 4b, and 4c TI-RADS categories had higher malignancy rates than those previously
reported in ND cytology. We think that TI-RADS categories in thyroid nodules with persistent ND cytology can be helpful in treatment
decision.
Key words: Nondiagnostic cytology, malignancy, thyroid imaging reporting and data system

1. Introduction
Ultrasound (US)-guided fine-needle aspiration (FNA)
is considered as the gold standard, accurate, costeffective, and safe procedure in evaluation of thyroid
nodules (1,2). However, FNA provides extremely
specific and sensitive test for pathologic diagnosis, it has
also some diagnostic limitations such as nondiagnostic
(ND), inadequate, or unsatisfactory results. The
estimated rate of malignancy in ND cytology has
been reported as 1%–4% in the literature, and in this
setting US-guided FNA repetition is recommended
(3). The incidence of ND cytology has been reported
in a wide range from 3% to 36.4% (2,4–7). A thyroid
nodule with ND cytology generally causes diagnostic
and therapeutic dilemma.

Thyroid US is a widely-used, noninvasive method in the
evaluation of thyroid nodules (8,9). High risk US features for
malignancy are solidity, irregular borders, microcalcifications,
marked hypoechogenicity, and more tall than wide shape
(8,10,11). The thyroid imaging reporting and data system (TIRADS) is useful in risk stratification of thyroid nodules by
using the number of high risk US features (12).
TI-RADS has been initially described in 2009 by two
independent teams led by Horvath et al. and Park et al.
(13,14). However, these systems are found as difficult to
apply in daily practice. Recently, Kwak et al. presented a more
convenient and simple system for TI-RADS classification
based on analysis of suspicious US features (12). Thereafter,
several different TI-RADS classifications have been proposed
(15–17).
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TI-RADS has been determined as an effective method
in malignancy prediction in thyroid lesions with various
cytologies (18). In the literature, there has been a few
studies evaluating the scoring systems and high risk US
features in malignancy prediction of nodules with ND
cytology (19,20). The aim of the present study was to
assess the utility of high risk US features and TI-RADS
in estimation of malignancy in thyroid nodules with
persistent (at least two FNAs) ND cytology.
2. Materials and methods
2.1. Study population
The medical records of 2998 patients who underwent
thyroidectomy were screened from January 2007 to
December 2016, retrospectively. US features, cytology,
and histopathology results of 12027 nodules in 2998
patients were recorded. Of 12027 nodules, 2646 (22%)
were determined as ND cytology. These 246 nodules with
≥2 ND cytologies were included in the study.
Average time between consecutive FNA procedures
was at least 3 month. ND nodules with subsequent
other cytologies such as benign, atypia of undetermined
significance/follicular lesion of undetermined significance
(AUS/FLUS), suspicious for follicular neoplasm (SFN),
suspicious for malignancy, and malignant were excluded.
Besides demographic information, preoperative
thyroid function tests (serum thyrotropin (TSH), free
triiodothyronine (fT3), free thyroxine (fT4), anti-thyroid
peroxidase antibody (anti-TPOAb), anti-thyroglobulin
antibody (anti-TGAb)), suspicious US findings, presence
of Hashimoto’s thyroiditis (HT), and final histopathology
results (malignant/benign) were obtained from medical
records. Diagnosis of HT in histopathology was based on
the presence of germinal centers, diffuse lymphocytic and
plasmacytic infiltration, and enlarged epithelial cells with
large nuclei and eosinophilic cytoplasm (Hurthle cells).
Serum TSH, fT3, fT4, anti-TPOAb, and anti-TgAb
levels were measured by chemiluminescence methods
(Immulite 2000, Diagnostic Products Corp., Los Angeles,
CA, USA and UniCel DXI 800, Beckman Coulter, Brea,
CA). The thyroid antibody level over the upper range of
normal was evaluated as positive.
Local ethical committee approval was obtained
according to the ethical standards of Helsinki declaration
(Approval date and number: 22nd March 2017-2017/63).
2.2. US examination
Thyroid US was performed using an Esaote color Doppler
US (Model 796FDII; MAG Technology Co. Ltd., Yung-Ho
City, Taipei, Taiwan) with a superficial probe (Model LA523
13–4, 5.5–12.5 MHz). US examinations were performed
by one of three endocrinologists, each with expertise in
thyroid US. Suspicious US features (microcalcifications,
hypoechogenicity, irregular borders, taller than wide
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shape, solidity) were noted retrospectively from the US
reports by an investigator. The model suggested by Kwak
et al. was used for determination of TI-RADS categories
(12). These categories were named as follows: category
3, nodules with no suspicious US feature; category 4a,
nodules with one suspicious feature; category 4b, nodules
with two suspicious features; category 4c, nodules with
three or four suspicious features; and finally category 5,
nodules with five suspicious US features (12). A TI-RADS
score was assigned to each nodule retrospectively by the
same investigator evaluating the US reports who was blind
to the pathology results.
2.3. Fine needle aspiration procedure
Informed consent was taken from all patients after giving
information about the FNA procedure. For the blood
thinner users, these medications were stopped temporarily
for 5 or more days before the procedure. FNA was carried
out with a 27-gauge needle and 20-mL syringe under
US guidance (Logic Pro 200 GE and 7.5 MHz probe,
Kyunggigo, Korea) by experienced endocrinologists.
Each nodule had average 2-3 passes from different sites.
Aspirated materials were expelled onto glass slides on-site.
FNA samples were air-dried and stained with Giemsa stain.
Cytopathologist was not on-site during the procedure.
The slides were evaluated off-side. The cytologic results
were reported according to the Bethesda classification.
Specimens having obscuring blood or insufficient amount
of follicular cells, and smears, which were overly thick or
air-dried alcohol-fixed, were evaluated as ND.
2.4. Statistical analysis
All data were analyzed with SPSS 15.0 software package
(SPSS Inc., Chicago, IL, USA). Descriptive statistics were
defined as mean±standard deviation (SD) for normally
distributed variables, median and range (min-max) for
nonnormally distributed variables, and as number of cases
(%) for nominal variables. Chi-square test was performed
in order to investigate the differences between the groups
for categorical variables. The comparisons between groups
were performed by Student’s t test and Mann–Whitney
U test for parametric and nonparametric variables,
respectively. A P value less than 0.05 was accepted as
statistically significant.
3. Results
Among 246 patients, final histopathological diagnosis
was benign in 218 (88.6%) and malignant in 28 (11.4%).
However, there were 57 (26.2%) male and 161 (73.8%)
female in benign group, 4 (14.3%) male and 24 (85.7%)
female patients were present in malignant group (P
= 0.171). There was no significant difference in mean
age between two groups (P = 0.068). Median TSH was
significantly higher in malignant group (P = 0.014). Serum
fT3 and fT4 were not statistically different between groups
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(P = 0.470 and P = 0.400, respectively). Moreover, there
was no significant difference in anti-TPOAb and antiTgAb positivity between benign and malignant groups (P
= 0.853 and P = 0.187, respectively). HT was present in 14
(50%) of 28 patients in malignant group and 70 (32.1%) of
218 patients in benign group (P = 0.060) (Table 1).
Among 28 nodules with malignant histopathology,
25 (89.3%) were a papillary thyroid carcinoma (PTC), 1
(3.6%) was a follicular thyroid carcinoma (FTC), 1 (3.6%)
was a medullary thyroid carcinoma (MTC), and 1 (3.6%)
was an undifferentiated thyroid carcinoma (UTC). Of
25 nodules with PTC, 10 (40%) had classical variant, 12
(48%) had follicular variant, 2 (8%) had encapsulated
follicular variant, and 1 (4%) had solid variant (Table 2).
No significant differences were detected in suspicious US
features between benign and malignant nodules (P > 0.05)
(Table 3).
Of 246 nodules with ND cytology, 12 (4.9%) were
assigned as TI-RADS 3, 53 (21.5%) as TI-RADS 4a, 104
(42.3%) as TI-RADS 4b, and 77 (31.3%) as TI-RADS 4c.
Thyroid nodule with TI-RADS 5 category was not detected.
No malignancies were detected in the group of nodules
assigned a TI-RADS 3 category. The malignancy rates of
TI-RADS category 4a, 4b, and 4c nodules were 13.2% (7 of
53 nodules), 9.6% (10 of 104 nodules), and 14.3% (11 of 77
nodules), respectively (Table 4). No significant differences
were detected in TI-RADS categories between benign and
malignant nodules (P > 0.05) (Table 3).

4. Discussion
The Bethesda system was suggested in 2009 to standardize
the terminology for interpreting cytology reports
among pathologists and laboratories, and to eliminate
diagnostic and therapeutic dilemmas. Although a small
number of cytologies represent Bethesda Category I
(ND), it is the most important limitation of thyroid FNA.
Furthermore, ND cytology results substantially affect
the management of nodules. Although, Bethesda system
recommended that ND cytology should not exceed 10%
of thyroid FNA, a wide range of its usage (up to 36.4%)
has been reported in the literature (3,7,21–26). Due to
the 1%–4% low risk of malignancy, the Bethesda system
recommends repetition of US-guided FNA in nodules
with ND cytologic results. This malignancy rate is similar
to the 0%–3% malignancy rate of benign cytology for
which clinical follow-up is recommended by the system
(3). In cases with ND cytology, actual management may
depend on other factors such as clinical and sonographic
features of nodules. Yet, there are currently no sufficient
data for the management of the nodules with persistent
ND FNAs. Due to the approximately 10% approved risk
of malignancy for persistent ND cytologies, surgery
may be considered in these nodules (27). In the present
study, the risk of malignancy was found as 11.4% (28 of
246). In our institution, 2646 (22%) of 12027 thyroid
nodules had ND cytology. Of 2646 ND nodules, 246
(9.3%) had persistent ND cytologies. The high rate of

Table 1. Demographic characteristics and baseline laboratory data of patients according to
benign and malignant final histopathology.
Benign
(n = 218)

Malignant
(n = 28)

P

Age (years)

51.09±11.15

46.64±11.83

0.068

Sex (M/F)

57/161

4/24

0.171

TSH (μIU/mL)

1.00
(0.007-9.34)

1.50
(0.002-6.15)

0.014

fT3 (pg/mL)

3.20
(1.57-6.96)

3.17
(2.14-4.39)

0.470

fT4 (ng/dL)

1.14
(0.68-2.47)

1.20
(0.70-1.67)

0.400

Anti TPO positivity (n,%)

n = 199
43 (21.6)

n = 25
5 (20.0)

0.853

Anti Tg positivity (n,%)

n = 192
49 (25.5)

n = 23
3 (13.0)

0.187

Presence of HT (n,%)

70 (32.1)

14 (50)

0.060

M: male, F: female, fT3: free triiodothyronine, fT4: free thyroxine, anti-TPOAb: anti-thyroid
peroxidase antibody, anti-TGAb: anti-thyroglobulin antibody, HT: Hashimoto’s thyroiditis in
histopathology. Significant P values are given in bold.
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Table 2.
group.

Distribution of histopathology results in malignant

Malignant
(n = 28)
PTC (n,%)

25 (89.3)

Classical variant

10 (40)

Follicular variant

12 (48)

Encapsulated follicular variant

2 (8)

Solid variant

1 (4)

FTC (n,%)

1 (3.6)

MTC (n,%)

1 (3.6)

UTC (n,%)

1 (3.6)

PTC: papillary thyroid carcinoma, FTC: follicular thyroid
carcinoma,
MTC: medullary thyroid carcinoma, UTC: undifferentiated
thyroid carcinoma.

ND cytology in our institiution can be associated wih
different operators performing the procedure, using
different aspiration techniques in the evaluation of fineneedle cytology, and different cytologists evaluating the
cytologies.
Suspicious US features associated with an increased
risk of malignancy are hypoechoic echogenicity, presence
of irregular borders, microcalcifications, solid pattern,
and taller than wide shape (28). We did not find any
difference in high risk US features between malignant
and benign groups in the present study. Furthermore, we
did not demonstrate any suspicious US finding predictive
for malignancy in thyroid nodules with persistent
ND cytology. Our study population included only the
operated patients with ND cytology. In these patients, we
decided surgery according to the presence of suspicious
US features, which might cause statistically insignificant
results between groups.
Several studies are present in the literature evaluating
the TI-RADS in ND cytology (19,20). Recently, Moon
et al. evaluated the US features of 548 ND nodules and
classified these nodules according to TI-RADS (19). In
their study, the malignancy risks for categories 3 and 4a
nodules were reported as 0.8% and 1.8%, respectively.
Moreover, the same authors found the malignancy rates
of categories 4b, 4c, and 5 nodules as 6.1%, 14.4%, and
31%, respectively (19). Yoon et al. stratified the nodules
with ND cytology according to TI-RADS before and after
application of the Bethesda system (20). They reported
the malignancy risks in category 3, 4a, 4b, 4c, and 5 as
1.8%, 5.7%, 4.1%, 29.8%, and 16.7% for the pre-Bethesda
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period, and 1.6%, 3.0%, 7.1%, 16.3%, and 25.0% for the
post-Bethesda period, respectively. They concluded that
similar malignancy rates were found in the pre- and
post-Bethesda periods (20). In the present study, no
malignancies were detected in the group of nodules with
TI-RADS category 3. Our malignancy risks of 4a, 4b, and
4c categories were 13.2%, 9.6%, and 14.3%, respectively.
Our study is different than those of Moon et al. and Yoon
et al. according to the study population. However, Moon
et al. studied all of ND nodules including the ones under
follow-up, Yoon et al. analyzed ND nodules on which
surgery had been performed, nodules at follow-up US
guided FNA that showed no significant change, and also
nodules with definitive benign or malignant cytologic
results at follow-up US-guided FNA (19,20). In our study,
we assessed the thyroid nodules with persistent ND
cytology, which were surgically removed. Nodules with
consecutive benign or malignant cytology, and nodules at
follow-up without operation were excluded. Thus, 100%
of nodules in our study have surgically proven histologies.
In the present study, no malignancies were detected
in the group of nodules assigned a TI-RADS category of
3. Due to the low risk of malignancy, it has been reported
that US follow-up can be considered for thyroid nodules
with ND cytology if high risk US features are not present
(19). Furthermore, this study demonstrated that the
malignancy rates of thyroid nodules with categories 4a,
4b, and 4c were 13.2%, 9.6% and 14.3%, respectively.
Thus, in these cases, repetition of US-guided FNA should
be considered (19). In the present study, malignancy risks
of nodules with categories 4a and 4c are near 15% which
is the cut-off for recommending surgery, so surgery can be
considered for these nodules (3).
Thyrotrophin is a major regulator of thyroid
hormone production by acting on thyroid follicular
cells. Furthermore, TSH consists of a vital role in normal
thyroid function and thyroid diseases (29,30). Recently,
it has been reported that TSH has a role in thyroid
malignancy development and progression, and acts like
a growth factor (31,32). Elevated TSH level was found
as a risk factor for thyroid malignancy (33–35). Boelaert
et al. demonstrated a higher malignancy rate in patients
with TSH levels between 1.0–1.7 mU/L compared to TSH
levels <0.4 mU/L, and furthermore a particularly higher
rate was found in patients with TSH levels more than 1.8
mU/L (35). In the present study, mean TSH level in the
malignant group was found higher as compared to the
benign group.
The follicular variant of PTC is the most common
subtype after classical variant, constituting between 10%
and 15% of all PTC cases (36,37). However, FNA is a
sensitive procedure, its reported sensitivity is significantly
low in follicular variant of PTC when compared to
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Table 3. Comparison of high risk US features and TI-RADS categories between histopathologically
benign and malignant groups.
Benign
(n = 218)

Malignant
(n = 28)

P

Nodule AP diameter (mm)

12.13±5.77

12.56±5.29

0.704

Nodule T diameter (mm)

15.48±7.64

14.62±7.82

0.583

Taller than wide shape (n,%)

35 (16.1)

5 (17.9)

0.808

Solidity (n,%)

203 (93.1)

28 (100)

0.358

Hypoechogenicity (n,%)

20 (9.2)

3 (10.7)

0.568

Microcalcification (n,%)

65 (29.8)

8 (28.6)

0.892

Irregular border (n,%)

126 (57.8)

18 (64.3)

0.512

TI-RADS 3

12 (5.5)

0

0.203

TI-RADS 4a

46 (21.1)

7 (25.0)

0.637

TI-RADS 4b

94 (43.1)

10 (35.7)

0.455

TI-RADS 4c

66 (30.3)

11 (39.3)

0.333

TI-RADS 5

0

0

-

TI-RADS (n, %)

AP: anteroposterior, T: transverse, TI-RADS: thyroid imaging reporting and data system.
Table 4. Histopathology results of nodules according to TI-RADS categories.
TI-RADS 3
n = 12

TI-RADS 4a
n = 53

TI-RADS 4b
n = 104

TI-RADS 4c
n = 77

Benign (n,%)

12 (100)

46 (86.8)

94 (90.4)

66 (85.7)

Malignant (n,%)

0

7 (13.2)

10 (9.6)

11 (14.3)

Test statistics

p

2.682

0.443

TI-RADS: thyroid imaging reporting and data system.

conventional PTC (38,39). In the present study, 89.3% (25
of 28 nodules) of patients with malignancy had PTC, of
which 48% was a follicular variant.
Our study had several limitations. Firstly, it has a
retrospective study design, which causes difficulty in
evaluating some factors. Secondly, we evaluated previous
US features only in the patients who underwent thyroid
surgery. However, in clinical practice, majority of the
patients with ND cytology are followed-up without
operation. In this study, only 9.3% of patients with ND
cytology were operated, most of our patients were going to
follow-up. Thus, our results should not be generalized to
all of nodules with ND cytology. Thirdly, the nodules with
ND cytology, which were operated also had suspicious
US features. As a result, our study population had a small
number of nodules with TI-RADS category 3. Fourthly,
the interval between consecutive US-guided FNAs was
not evaluated in our study. In the Bethesda system, for
reparation of atypia, although FNA is recommended after

3 months, the optimal interval between two procedures is
not described clearly. Some authors recommend further
FNA within the following 6–12 months (3,23,40). In our
institution, repeat FNA was generally performed at least 3
months after the previous procedure.
In conclusion, we found malignancy rate as 11.4%
in thyroid nodules with persistent ND cytology.
Furthermore, we did not demonstrate any suspicious
US finding predictive for malignancy in thyroid nodules
with persistent ND cytology and did not determine any
difference between malignant and benign nodules in TIRADS scores. In the evaluation of TI-RADS categories for
all nodules with persistent ND cytologies, no malignancy
was detected in TI-RADS category 3 but malignancy rate
was increased to 14.3% in TI-RADS 4 category. However,
there are currently no sufficient data for the management
of the nodules with persistent ND, TI-RADS categories
can be helpful for the clinician in the treatment decision
of these nodules.
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